Brunex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 10-01-2025
- Paid Up Capital ₹ 0.10 M
as on 10-01-2025
- Company Age 10 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2018)
- Profit 15.54%
(FY 2018)
- Ebitda -28.38%
(FY 2018)
- Net Worth -7.83%
(FY 2018)
- Total Assets -7.38%
(FY 2018)
About Brunex Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Siddesha Malleswaraswamy, Sree Deva, Bhaskar Erugandindla, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74900KA2014PTC076638
- Company No.
076638
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Sep 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Brunex Pharmaceuticals?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Veera Oleti  | Additional Director | 05-Mar-2022 | Current |
| Siddesha Malleswaraswamy | Director | 29-Sep-2014 | Current |
| Sree Deva | Director | 29-Sep-2014 | Current |
| Bhaskar Erugandindla | Additional Director | 05-Mar-2022 | Current |
| Daskhinamurthy Jayamala | Additional Director | 17-Mar-2022 | Current |
Financial Performance of Brunex Pharmaceuticals.
Brunex Pharmaceuticals Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 15.54% increase in profit. The company's net worth dipped by a decrease of 7.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brunex Pharmaceuticals?
In 2018, Brunex Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Elv Projects Private LimitedActive 9 years 1 monthBhaskar Erugandindla and Veera Oleti are mutual person
_PRIVATE_LIMITED.webp)
Akruti Homes (Bangalore) Private LimitedActive 17 years 2 monthsBhaskar Erugandindla and Veera Oleti are mutual person
- Elv Mines And Minerals Private LimitedActive 2 years 6 months
Bhaskar Erugandindla and Veera Oleti are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Brunex Pharmaceuticals?
Unlock and access historical data on people associated with Brunex Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brunex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brunex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
